38 results about "Megakaryocyte Progenitor Cells" patented technology

The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.

The invention discloses a method for amplifying a megakaryocyte progenitor cell from a human cord blood CD34<+> cell, which comprises the following steps: vaccinating a cord blood CD34<+> hemopoieticprogenitor cell obtained by magnetic-activated cell sorting on an illuminated human bone mesenchymal stem cell; culturing for 7days in a serum-free culture medium containing recombinant human thrombopoietin (rhTPO); and analyzing the effect of amplifying the megakaryocyte progenitor cell by cell counting, flow cytometry detection and a megacaryocyte cell colony forming assay (CFU-MK assay). Compared with the prior method, the method for amplifying the megakaryocyte progenitor cell has the culture condition more approaching to the natural medullary hemopoiesis microenvironment in vivo, and botha cell factor secreted by the mesenchymal stem cell and the added rhTPO conform to the clinical application standard. Accordingly, the invention provides a new path for the invitro amplification of the megakaryocyte progenitor cell.

The invention belongs to the field of cell technology, and in particular relates to a method for improving the differentiation efficiency of umbilical cord blood megakaryocyte progenitor cells in vitro. In the present invention, the type I stem cell culture medium containing 50 μmol / L resveratrol is added to the total nucleated cells of the umbilical cord blood for 72 hours, and the type II stem cell culture medium without resveratrol is replaced to continue the culture, and finally the High differentiation efficiency of megakaryotic progenitor cells. The present invention discloses that after culturing and treatment with Type I stem cell medium containing 50 μmol / L resveratrol, and then replacing Type II stem cell medium without any resveratrol component to continue culturing, through successive cultivation of these two mediums Sequential combination can significantly improve the efficiency of directional differentiation of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, and can prepare megakaryotic progenitor cells with higher purity. The process of the method is simple, reliable and repeatable, the possibility of pollution is low, and the economy of the preparation cost and the operation safety are taken into consideration.

The invention relates to the field of cell culture, in particular to cell cryopreservation liquid, application thereof and a cryopreservation method of megakaryocyte progenitor cells. The cell cryopreservation liquid comprises DMSO, fetal calf serum, dextran, trehalose and albumin. By means of the cell cryopreservation liquid, the cytoactive of the megakaryocyte progenitor cells can be well maintained during the cryopreservation period, and damage to cells in the cryopreservation and resuscitation processes is lowered. According to the cell cryopreservation liquid, application thereof and the cryopreservation method of the megakaryocyte progenitor cells, the cryopreservation and temperature reduction processes are softer, the cells are stored in liquid nitrogen after the temperature reduction process is conducted, the influence on the cytoactive is small, and damage to the cells in the cryopreservation process is lowered. It is indicated by experiments that the vigour of the resuscitated cells can reach 94% one month after the megakaryocyte progenitor cells are cryopreservated in the cryopreservation liquid, and multiplication activity is good, and the cell cryopreservation liquid is significantly superior to the prior art.

The invention discloses a method for increasing the number of directional differentiation of umbilical cord blood megakaryocyte progenitor cells. In this method, umbilical cord blood hematopoietic stem cells are used as sample cells, and directed differentiation is carried out in a specific medium containing resveratrol. The specific medium containing resveratrol makes the operation of directed differentiation of megakaryotic progenitor cells easier, safer and more efficient. In the process of directional differentiation and culture of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, resveratrol is added together with cytokines to achieve the effect of increasing the number of megakaryotic progenitor cells. The method of the present invention is easy to operate and low in cost. Cell safety is high.

Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.

The invention relates to the technical field of a stem cell preparation, in particular to a megakaryocyte progenitor cell preparation as well as application and a preparation method thereof. The megakaryocyte progenitor cell preparation consists of megakaryocyte progenitor cells, human albumin, a stem cell growth factor, interleukin-2 and a safflower injection. The megakaryocyte progenitor cell preparation disclosed by the invention has a significant effect on improving aleucia; after infusion, platelet content in patients, as being recovered, can be kept at a normal level for a relatively long time in vivo; and the megakaryocyte progenitor cell preparation, after being applied, is free from any adverse reaction and safe to use, and the megakaryocyte progenitor cell preparation is simple in preparation and convenient to use.